Lilly details its robust R&D pipeline to investment community

In a presentation to the investment community today, US pharma major Eli Lilly (NYSE: LLY) said it has the potential to launch 20 new products in the 10 years beginning in 2014 and extending through 2023. In addition, Lilly could launch an average of two new indications or line extensions for already-approved products per year during that same time period.

"We're pleased to share with investors the breadth and depth of the Lilly pipeline, which showcases our progress across our key therapeutic areas. This includes recent launches as well as a robust line-up of assets in late-stage development or already under regulatory review," said John Lechleiter, Lilly's chairman, president and chief executive. "There are no guarantees given the nature of science and of our business; however, in looking at our recent launches and current pipeline, we believe we are in the midst of the most prolific period of new launches in our company's 140-year history," he added.

Lilly's R&D efforts focus on five therapeutic areas where the company has assets and capabilities that enable it to compete successfully. These include four core areas - diabetes, oncology, immunology and neurodegeneration - and one emerging area - pain. Today's presentation highlighted the company's R&D strategy and progress in diabetes, oncology, immunology and pain.